SciSparc Ltd. (SPRC) Form 6-K — Oct 23, 2026

SciSparc's majority-owned subsidiary NeuroThera Labs has completed manufacturing of SCI-110 and obtained European Qualified Person batch release certification for its FDA-approved Phase IIb Tourette syndrome trial. QP release authorizes shipment of clinical trial material to study sites, a key regulatory milestone. All three clinical sites — Yale Child Study Center, Hannover Medical School, and Tel Aviv Sourasky Medical Center — have completed site initiation and are prepared to receive drug supplies, with patient enrollment now imminent.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.